Physician profile
James E Tomblin
NPI 1518959055
$3,064.73
in general payments reported to CMS, 2019-2025
37 companies · $308 in 2025
The $308 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $131 · 2021: $423 · 2022: $1,054 · 2023: $633 · 2024: $345 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,286.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $626.13 | 2019-2023 | Lo Loestrin Fe, Ubrelvy |
| Caldera Medical, INC | $314.38 | 2022 | |
| Mayne Pharma Commercial LLC | $272.04 | 2022-2025 | |
| Astellas Pharma US INC | $245.16 | 2019-2025 | Veozah |
| Hologic Sales and Service, LLC | $182.91 | 2021-2023 | Coolseal Generator |
| Evofem Biosciences, INC. | $170.56 | 2021-2025 | Phexxi, Solosec, Phexx |
| Avion Pharmaceuticals | $133.83 | 2019-2022 | |
| Biogen, INC. | $126.15 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $110.34 | 2019-2023 | Slynd |
| Pfizer INC. | $101.24 | 2021-2025 | |
| Agile Therapeutics, INC. | $64.05 | 2021-2023 | Twirla |
| Daiichi Sankyo INC. | $59.16 | 2020-2021 | |
| Organon LLC | $58.81 | 2021-2023 | Nexplanon |
| Allergan, INC. | $56.60 | 2019 | |
| Shield Therapeutics INC | $47.64 | 2024-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $46.35 | 2023 | Myfembree |
| Davol INC. | $42.51 | 2020-2023 | Arista Ah Flexitip |
| Eisai INC. | $42.09 | 2020-2021 | |
| Exact Sciences Corporation | $39.45 | 2023 | Cologuard Collection Kit |
| Myovant Sciences INC. | $31.19 | 2021-2022 | |
| Novo Nordisk INC | $27.52 | 2023-2024 | Wegovy |
| Therapeuticsmd, INC. | $26.27 | 2020-2022 | |
| Pacira Pharmaceuticals Incorporated | $25.92 | 2025 | Exparel |
| Bayer Healthcare Pharmaceuticals INC. | $23.82 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $18.77 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.61 | 2022 | |
| Millicent US INC | $18.56 | 2024 | Femring, Intrarosa |
| Coopersurgical, INC. | $18.01 | 2019 | |
| Amgen INC. | $15.77 | 2022 | |
| Lilly USA, LLC | $15.26 | 2025 | Zepbound |
| Sanofi Pasteur INC. | $14.19 | 2025 | |
| Currax Pharmaceuticals LLC | $14.12 | 2020 | |
| Merck Sharp & Dohme LLC | $12.84 | 2022 | |
| Mylan Pharmaceuticals INC. | $12.54 | 2021 | |
| Vertical Pharmaceuticals, LLC | $11.89 | 2019 | |
| Lupin INC. | $11.34 | 2020 | |
| Meditrina | $8.71 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Tomblin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.